Australian Gonococcal Surveillance Programme Annual Report, 2022
Communicable Diseases Intelligence · 2023
DOI: 10.33321/cdi.2023.47.45 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2023. Verfasst von Monica M Lahra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neisseria Reference Laboratory and World Health Organization Collaborating Centre for STI and AMR, Sydney. NSW Health Pathology, Microbiology, The Pr…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gonorrhea, Neisseria gonorrhoeae, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Abstract (Originalsprache)
The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae for more than 40 years. In 2022, a total of 8,199 isolates from patients in the public and private sectors, in all jurisdictions, were tested for in vitro antimicrobial susceptibility by standardised methods. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2022, of N. gonorrhoeae isolates tested, 0.51% (42/8,199) met the WHO criterion for ceftriaxone decreased susceptibility (DS), defined as a minimum inhibitory concentration value ≥ 0.125 mg/L. Resistance to azithromycin was reported in 3.9% of N. gonorrhoeae isolates, proportionally stable since 2019. There were nine isolates with high-level resistance to azithromycin (MIC value ≥ 256 mg/L) reported in Australia: Queensland (4), New South Wales (3), Victoria (1) and non-remote Western Australia (1). This is the highest number detected annually by the AGSP. In 2022, penicillin resistance was found in 38.8% of gonococcal isolates, and ciprofloxacin resistance in 63.3%, however, there was considerable variation by jurisdiction. In some remote settings, penicillin resistance remains low; in these settings, penicillin continues to be recommended as part of an empiric therapy strategy. In 2022, in remote Northern Territory, one penicillin-resistant isolate was reported; in remote Western Australia, 11.8% of gonococcal isolates (9/76) were penicillin resistant. There were three ciprofloxacin-resistant isolates reported from remote Northern Territory; ciprofloxacin resistance rates remain comparatively low in remote Western Australia (6/76; 7.9%).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neisseria Reference Laboratory and World Health Organization Collaborating Centre for STI and AMR, Sydney. NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031, Australia; School of Medi…
- New South Wales Health Pathology, Microbiology, Royal Prince Alfred Hospital Camperdown, NSW, Australia; School of Medicine, University of Sydney.
- Neisseria Reference Laboratory and World Health Organization Collaborating Centre for STI and AMR, Sydney. NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031, Australia.
Zitieren
APA
Lahra, M. M., Van Hal, S., & Hogan, T. R. (2023). Australian Gonococcal Surveillance Programme Annual Report, 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2023.47.45
Vancouver
Lahra MM, Van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report, 2022. Communicable Diseases Intelligence. 2023. doi:10.33321/cdi.2023.47.45
BibTeX
@article{Lahra2023,
author = {Lahra, Monica M and Van Hal, Sebastiaan and Hogan, Tiffany R},
title = {Australian Gonococcal Surveillance Programme Annual Report, 2022},
journal = {Communicable Diseases Intelligence},
year = {2023},
doi = {10.33321/cdi.2023.47.45}
}
EUVIMED